Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.65 |
| ▸ | ENPP1 | P22413 | 6/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 2/20 | 0.63 |
| ▸ | BACE1 | P56817 | 2/20 | 0.63 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22441523 | 0.83 | ENPP1 (0.71) | PDE10AENPP1MAPK1ACHEBACE1 | |
| SCHEMBL4969095 | 0.82 | MAPK1 (0.74) | PDE10AENPP1MAPK1ACHEBACE1 | |
| SCHEMBL10618244 | 0.82 | MAPK1 (0.74) | PDE10AENPP1MAPK1ACHEBACE1 | |
| SCHEMBL20782445 | 0.82 | ENPP1 (0.74) | PDE10AENPP1MAPK1ACHEBACE1 | |
| SCHEMBL7276406 | 0.82 | ENPP1 (0.73) | PDE10AENPP1MAPK1ACHEBACE1 | |
| SCHEMBL4965743 | 0.82 | ENPP1 (0.70) | PDE10AENPP1MAPK1ACHEBACE1 | |
| SCHEMBL22291145 | 0.81 | ENPP1 (0.69) | PDE10AENPP1MAPK1ACHEBACE1 | |
| SCHEMBL22441471 | 0.81 | NCF1 (0.59) | PDE10AMAPK1PDE3BPDE3A | |
| Hydrochloric Acid SCHEMBL22441562 | 0.81 | ENPP1 (0.72) | PDE10AENPP1MAPK1ACHEBACE1 | |
| Hydrochloric Acid SCHEMBL29357602 | 0.81 | ENPP1 (0.72) | PDE10AENPP1MAPK1ACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3941459-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113924092-A | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020190912-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ENPP1, ENPP3, PDE7A | PDE10A 482/4885ENPP1 1/4885MAPK1 1106/4885 |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | ENPP1, ENPP3, PDE7A | PDE10A 482/4885ENPP1 1/4885MAPK1 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.